Expand Document  |  Expand Chapter  |  Full TOC  |  Printable HTML version
WHO Expert Committee on Specifications for Pharmaceutical Preparations - WHO Technical Report Series, No. 863, Annex 11 (Guidelines for the Assessment of Herbal Medicines) - Thirty-fourth Report
(1996; 8 pages) [French] [Spanish]
Table of Contents
View the documentIntroduction
View the documentAssessment of quality
View the documentAssessment of safety
View the documentAssessment of efficacy
View the documentIntended use
View the documentUtilization of these guidelines

Intended use

Product information for the consumer

Product labels and package inserts should be understandable to the consumer or patient. The package information should include all necessary information on the proper use of the product.

The following elements of information will usually suffice:

• name of the product
• quantitative list of active ingredient(s)
• dosage form
• indications

- dosage (if appropriate, specified for children and the elderly)
- mode of administration
- duration of use
- major adverse effects, if any
- overdosage information
- contraindications, warnings, precautions and major drug interactions
- use during pregnancy and lactation

• expiry date
• lot number
• holder of the marketing authorization.

Identification of the active ingredient(s) by the Latin botanical name, in addition to the common name in the language of preference of the national regulatory authority, is recommended.

Sometimes not all information that is ideally required may be available, so drug regulatory authorities should determine their minimal requirements.


Advertisements and other promotional material directed to health personnel and the general public should be fully consistent with the approved package information.


to previous section
to next section
The WHO Essential Medicines and Health Products Information Portal was designed and is maintained by Human Info NGO. Last updated: December 6, 2017